- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04309058
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism
Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism,a Prospective Cohort Study
Aims:Prospectively observe the effects of Vitamin D drops supplementation on the chronic course of ulcerative colitis patients, analyze whether the effect of Vitamin D drops on UC patients is affected by factors such as disease site, disease activity, treatment, etc.Exploring the relationship between Fok I gene polymorphism and the efficacy of vitamin D supplementation. Provide a certain theoretical basis for "precision treatment" for UC patients in the future.
Design:It is a prospective cohort study. Investigators include a total of 100 participants with UC according to the inclusion and exclusion criteria, and divide them into two groups to assess their initial disease activity and detect related indicators. At the same time,investigators detect the Fok I gene polymorphism in all participants.One group is given Vitamin D drops 400IU per day orally, and the control group do not intervene. Participants' disease activity is assessed at baseline and related indicators are determined. The disease activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the serum indexes are re-evaluated.Investigators use statistical methods to analyze whether Vitamin D drops supplementation treatment can increase the serum 25 (OH) D level of UC participants, improve the condition of UC participants,relationship with Fok I gene polymorphism,and analyze the effects of Vitamin D drops on participants with UC is affected by factors such as disease site, disease activity, and treatment.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
- The research can be started only after approval by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.
- According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease" formulated by the Beijing Conference in 2018 as a standard, patients with clear diagnosis of UC are collected.Other diagnostic criteria include Vitamin D deficiency (<= 20ng / ml). Exclusion criteria included pregnancy, breastfeeding, liver and kidney dysfunction, concurrent autoimmune diseases, and use of antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes.
- Assess disease activity of UC participants based on the "Moya score".
- General information about participants with UC is collected.
- Detection of Fok I gene polymorphism using Snapshot technology.
- The level of serum 25 (OH) D of participants is detected.
- Serum C-reactive protein, erythrocyte sedimentation rate, albumin, calcium and phosphorus levels are measured.
- Develop a treatment plan for all participants.
- Participants are divided into two groups, one group is given oral Vitamin D drops 400IU/ d, and the other group do not intervene.
- The disease activity is re-evaluated in the 3rd, 6th, 9th, and 12th months, and the above serum indexes are re-evaluated.
Follow-up for 12 months. By comparing the above indicators, observe that in the Han population:
- Can Vitamin D drops supplementation increase serum 25 (OH) D levels in patients with UC?
- Can Vitamin D drops supplementation improve the condition of patients with UC?
- Whether Fok I gene polymorphism affect the efficacy of Vitamin D drops supplementation therapy?
- Whether the effects of Vitamin D drops on UC patients is affected by factors such as disease site, disease activity, treatment, etc ..
- Through statistical analysis, comprehensive analysis of the effectiveness and safety of Vitamin D drops supplementation in Han patients with UC, and its relationship with Fok I gene polymorphism, providing a theoretical basis for further "precise treatment" intervention in inflammatory bowel disease.
Studietype
Inschrijving (Verwacht)
Fase
- Vroege fase 1
Contacten en locaties
Studie Locaties
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- SAHWenzhouMU
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Clearly diagnosed patients with UC
- Vitamin D deficiency (<= 20ng / ml)
Exclusion Criteria:
- Pregnancy, lactation
- Liver and kidney insufficiency
- Co-morbid with other autoimmune diseases
- Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes
- Vitamin D level is normal or high
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Controle
De andere groep bemoeit zich er niet mee.
|
|
|
Experimenteel: Vitamine D daalt
Deze groep patiënten gaat vitamine D druppels 400IU/d oraal aanvullen.
|
Vitamin D-deficient UC patients are divided into two groups, one group is given orally with Vitamin D drops 400IU / d, while the other group do not interfere.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Genotype frequency of vitamin D receptor single nucleotide polymorphisms in participants
Tijdsspanne: 1 year
|
Genotype frequency of vitamin D receptor single nucleotide polymorphisms in participants can reflect whether it is related to the severity of the disease and how much relevance.
|
1 year
|
|
Serum 25 (OH) D level
Tijdsspanne: 1year
|
Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status
|
1year
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
bezinkingssnelheid van erytrocyten
Tijdsspanne: 1 jaar
|
ESR kan worden gebruikt om de mate van ontsteking in het lichaam weer te geven.
|
1 jaar
|
|
Blood calcium and phosphorus
Tijdsspanne: 1year
|
Monitoring serum calcium and phosphorus levels to prevent toxic side effects.
|
1year
|
|
Concentration of C-reactive protein in participants
Tijdsspanne: 1year
|
Concentration of C-reactive protein can be used to reflect the degree of inflammation in the human body.
|
1year
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Jiang yi, PhD, Second Affiliated Hospital of Wenzhou Medical University
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van het spijsverteringsstelsel
- Pathologische processen
- Gastro-intestinale aandoeningen
- Voedingsstoornissen
- Gastro-enteritis
- Colon Ziekten
- Darmziekten
- Avitaminose
- Deficiëntie Ziekten
- Ondervoeding
- Inflammatoire darmziekten
- Zweer
- Vitamine D-tekort
- Colitis
- Colitis, ulceratief
- Fysiologische effecten van medicijnen
- Micronutriënten
- Vitaminen
- Behoudsmiddelen voor botdichtheid
- Vitamine D
Andere studie-ID-nummers
- SAHoWMU-CR2017-01-121
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .